Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 8/20 | 0.48 |
| ▸ | BRD4 | O60885 | 4/20 | 0.45 |
| ▸ | CBX7 | O95931 | 1/20 | 0.43 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.43 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.43 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2495393 | 0.89 | KMT2A (0.57) | KMT2ABRD4CBX7CDYLKCNQ3 | |
| SCHEMBL2492693 | 0.89 | BRD4 (0.46) | KMT2APGRBRD4CBX7CDYL | |
| SCHEMBL1464565 | 0.86 | KMT2A (0.72) | KMT2ACBX7CDYLKCNQ3KCNQ2 | |
| SCHEMBL2497429 | 0.83 | CBX7 (0.52) | KMT2ABRD4CBX7CDYLKCNQ3 | |
| SCHEMBL2497604 | 0.83 | KMT2A (0.51) | KMT2ABRD4CBX7CDYLKCNQ3 | |
| SCHEMBL5860255 | 0.82 | KMT2A (0.50) | KMT2ABRD4CBX7CDYLKCNQ3 | |
| SCHEMBL2499035 | 0.82 | KMT2A (0.53) | KMT2ABRD4CBX7CDYLKCNQ3 | |
| SCHEMBL5857998 | 0.82 | KMT2A (0.53) | KMT2ACBX7CDYLKCNQ3KCNQ2 | |
| SCHEMBL2495455 | 0.81 | KCNQ3 (0.51) | KMT2ABRD4CBX7CDYLKCNQ3 | |
| SCHEMBL2495110 | 0.81 | KMT2A (0.48) | KMT2ABRD4CBX7CDYLKCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | AVPR1B, AVPR1A, AVPR2 | KMT2A 1662/4885PGR 413/4885BRD4 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.